High-Tech Gründerfonds and Technologiegründerfonds Sachsen invest in denovoMATRIX‘ vision of enabling human biology in vitro.

Dr. Fabian Mohr, Investment Manager at HTGF: “In order to be able to offer high-quality stem cell therapies in the future, manufacturers must keep their variability in cell cultivation low. denovoMATRIX products offer a chemically defined solution to this problem, which we hope will provide a good basis for the translation of stem cell therapies from research into clinical practice.

Take a look at the press release from High-Tech Gründerfonds (ENG) and the article of Technologiegründerfonds Sachsen (GER) for more information.